117 related articles for article (PubMed ID: 36336224)
21. Low-dose-rate Brachytherapy for Prostate Cancer in Low-resource Settings.
Echevarria MI; Naghavi AO; Abuodeh YA; Ahmed KA; Chevere C; Fernandez D; Yamoah K
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):378-382. PubMed ID: 28871987
[TBL] [Abstract][Full Text] [Related]
22. Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer.
Gogineni E; Rana Z; Soberman D; Sidiqi B; D'Andrea V; Lee L; Potters L; Parashar B
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1232-1242. PubMed ID: 33171199
[TBL] [Abstract][Full Text] [Related]
23. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System.
Yamoah K; Lee KM; Awasthi S; Alba PR; Perez C; Anglin-Foote TR; Robison B; Gao A; DuVall SL; Katsoulakis E; Wong YN; Markt SC; Rose BS; Burri R; Wang C; Aboiralor O; Fink AK; Nickols NG; Lynch JA; Garraway IP
JAMA Netw Open; 2022 Jan; 5(1):e2144027. PubMed ID: 35040965
[TBL] [Abstract][Full Text] [Related]
24. Curative brachytherapy for prostate cancer in African-Caribbean patients: A retrospective analysis of 370 consecutive cases.
Atallah V; Leduc N; Creoff M; Sargos P; Taouil T; Escarmant P; Vinh-Hung V
Brachytherapy; 2017; 16(2):342-347. PubMed ID: 28024937
[TBL] [Abstract][Full Text] [Related]
25. Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data.
Loblaw A; Pickles T; Crook J; Martin AG; Vigneault E; Souhami L; Cury F; Morris J; Catton C; Lukka H; Cheung P; Sethukavalan P; Warner A; Yang Y; Rodrigues G;
Clin Oncol (R Coll Radiol); 2017 Mar; 29(3):161-170. PubMed ID: 27780694
[TBL] [Abstract][Full Text] [Related]
26. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer.
Burri RJ; Stone NN; Unger P; Stock RG
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1338-44. PubMed ID: 20138442
[TBL] [Abstract][Full Text] [Related]
28. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
29. Low-dose-rate prostate brachytherapy: 4-8 week postimplant prostate-specific antigen a novel predictor of biochemical failure-free survival.
Callaghan CM; Wang L; Alluri A; Lauve A; Boyer C; Russell W
Brachytherapy; 2017; 16(6):1119-1128. PubMed ID: 28844821
[TBL] [Abstract][Full Text] [Related]
30. High-intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy.
Pickles T; Morris WJ; Keyes M
Brachytherapy; 2017; 16(6):1101-1105. PubMed ID: 29032014
[TBL] [Abstract][Full Text] [Related]
31. I-125 or Pd-103 for brachytherapy boost in men with high-risk prostate cancer: A comparison of survival and morbidity outcomes.
Stone NN; Skouteris VM; Rosenstein BS; Stock RG
Brachytherapy; 2020; 19(5):567-573. PubMed ID: 32763013
[TBL] [Abstract][Full Text] [Related]
32. Results of 14 years of brachytherapy for localized prostate cancer in Denmark: the Herlev cohort.
Jacobsen MG; Thomsen FB; Fode M; Bisbjerg R; Østergren PB
Scand J Urol; 2018 Apr; 52(2):164-168. PubMed ID: 29463165
[TBL] [Abstract][Full Text] [Related]
33. Long-Term Prostate Specific Antigen Stability and Predictive Factors of Failure after Permanent Seed Prostate Brachytherapy.
Tetreault-Laflamme A; Crook J; Hamm J; Pickles T; Keyes M; McKenzie M; Pai H; Bachand F; Morris J
J Urol; 2018 Jan; 199(1):120-125. PubMed ID: 28827105
[TBL] [Abstract][Full Text] [Related]
34. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
35. Radical dose escalation by high-dose-rate brachytherapy for localized prostate cancer-Significance of prostate-specific antigen nadir level within 18 months as correlation for long-term biochemical control.
Schroeder C; Geiger F; Siebert FA; Baumann R; Bockelmann G; Schultze J; Kimmig B; Dunst J; Galalae R
Brachytherapy; 2019; 18(1):8-12. PubMed ID: 30482622
[TBL] [Abstract][Full Text] [Related]
36. Treatment results of brachytherapy vs. external beam radiation therapy for intermediate-risk prostate cancer with 10-year followup.
Goy BW; Soper MS; Chang T; Slezak JM; Cosmatos HA; Tome M
Brachytherapy; 2016; 15(6):687-694. PubMed ID: 27600607
[TBL] [Abstract][Full Text] [Related]
37.
Kindts I; Stellamans K; Billiet I; Pottel H; Lambrecht A
Strahlenther Onkol; 2017 Sep; 193(9):707-713. PubMed ID: 28488030
[TBL] [Abstract][Full Text] [Related]
38. Long-term biochemical outcomes using cesium-131 in prostate brachytherapy.
Moran BJ; Rice SR; Chhabra AM; Amin N; Braccioforte M; Agarwal M
Brachytherapy; 2019; 18(6):800-805. PubMed ID: 31427178
[TBL] [Abstract][Full Text] [Related]
39. Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma.
Yamoah K; Eldredge-Hindy HB; Zaorsky NG; Palmer JD; Doyle LA; Sendecki JA; Hesney AA; Harper L; Repka M; Showalter TN; Hurwitz MD; Dicker AP; Den RB
Brachytherapy; 2014; 13(5):456-64. PubMed ID: 24953945
[TBL] [Abstract][Full Text] [Related]
40. Long-term oncologic outcomes of low dose-rate brachytherapy compared to hypofractionated external beam radiotherapy for intermediate -risk prostate cancer.
Sanmamed N; Joseph L; Crook J; Craig T; Warde P; Tomasso AD; Chung P; Berlin A; Bayley A; Saibishkumar EP; Glicksman R; Raman S; Catton C; Helou J
Brachytherapy; 2023; 22(2):188-194. PubMed ID: 36549968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]